Australian (ASX) Stock Market Forum

TSN - The Sustainable Nutrition Group

Jump to new
This one's really in an upwards trend lately. Hit a intra-high of .64 today :)

Surely the update on approval must be getting close
 
This one just keeps going up, even on days when the market is down. With potential FDA approval due any day now, (if good) the higher this one is to begin with, potentially the higher it could fly.
 
Well someone's deleted peoples' last two posts. I can't really speculate what investors will value ACL with a positive FDA approval. SP has been creeping up lately and if it comes through, realistically this one could go much higher of course. If it goes ahead and cash comes in, I think previous valuations mentioned on here are not out of question. :)
 
Hmm, seems to have gone down half a cent recently. What's the concensus, is there some sort of news I've missed or is this just people jumping ship while theyre ahead?
 
There are a lot of announcements out. I watched my modest parcel of ACL shares diminish by 7% today, probably due to share dilution because of the rights issue announced today:

Brisbane, Australia, 25 November 2009: Alchemia Limited’s (ASX:ACL) Board of Directors today
announced that the Company will be undertaking a renounceable Rights issue. The Rights issue will provide
eligible shareholders of the Company with an opportunity to apply for new fully paid ordinary Alchemia
shares at $0.53 per share, with no brokerage costs and a discount of 26.9% to the closing price of the
Shares of $0.725 on 24 November 2009, being the last day of trading before the announcement of the
Issue.​

Every 11 shares held at 3/12/09 is eligible to receive 2 additional shares at 53c.

So, with the pending approval and market launch of fondaparinux, why raise funds at this time? The Issue
will enable Alchemia to markedly accelerate several programs that the Company believes have the potential
to add considerable additional value to shareholders, by bringing forward other key milestones by up to 9
months. Whilst the commencement of the single Phase III trial for HA-Irinotecan will be the primary use of
the proceeds, the other programs to which the funds will be applied include:

• pre-clinical research evaluating the effectiveness of the HyACT platform in targeting cancer stem cells;
• preparing for the Company’s filing for approval of fondaparinux in the European market;
• assessing the viability of delivering fondaparinux sodium in an oral dosage form; and
• the support for a physician initiated Phase I/IIa trial for HA-Irinotecan as a cancer stem cell targeted
therapy in first line treatment of extensive Small Cell Lung Cancer.

With so many opportunities at the Company’s doorstep, it is the Board’s strong belief that it is in the best
interest of shareholders that the Company has adequate funding to expedite these programs. This will
ensure the Company can deliver ongoing and timely product opportunities from its pipeline which, if
successful, will ultimately drive shareholder value beyond that achievable by fondaparinux alone​

link

The shares closed at 67.5c.
 
GoodCall said:
There are a lot of announcements out. I watched my modest parcel of ACL shares diminish by 7% today, probably due to share dilution because of the rights issue announced today:

Brisbane, Australia, 25 November 2009: Alchemia Limited’s (ASX:ACL) Board of Directors today
announced that the Company will be undertaking a renounceable Rights issue. The Rights issue will provide
eligible shareholders of the Company with an opportunity to apply for new fully paid ordinary Alchemia
shares at $0.53 per share, with no brokerage costs and a discount of 26.9% to the closing price of the
Shares of $0.725 on 24 November 2009, being the last day of trading before the announcement of the
Issue.​

Every 11 shares held at 3/12/09 is eligible to receive 2 additional shares at 53c.

So, with the pending approval and market launch of fondaparinux, why raise funds at this time? The Issue
will enable Alchemia to markedly accelerate several programs that the Company believes have the potential
to add considerable additional value to shareholders, by bringing forward other key milestones by up to 9
months. Whilst the commencement of the single Phase III trial for HA-Irinotecan will be the primary use of
the proceeds, the other programs to which the funds will be applied include:

• pre-clinical research evaluating the effectiveness of the HyACT platform in targeting cancer stem cells;
• preparing for the Company’s filing for approval of fondaparinux in the European market;
• assessing the viability of delivering fondaparinux sodium in an oral dosage form; and
• the support for a physician initiated Phase I/IIa trial for HA-Irinotecan as a cancer stem cell targeted
therapy in first line treatment of extensive Small Cell Lung Cancer.

With so many opportunities at the Company’s doorstep, it is the Board’s strong belief that it is in the best
interest of shareholders that the Company has adequate funding to expedite these programs. This will
ensure the Company can deliver ongoing and timely product opportunities from its pipeline which, if
successful, will ultimately drive shareholder value beyond that achievable by fondaparinux alone​

link

The shares closed at 67.5c.
Click to expand...

Dilution has occured yet. The FDA news is supposed to come out somewhere in between the last days of the rights offer and the time they are allocated.
Seems fairly risky.
 
Been a long wait for this one. The new company presentation suggests that the FDA approval will happen by March... up from low 60's to mid 70 cents in the last few days... perhaps some have more information than me. SP should hit $1 with positive announcement... but there have been a lot of people waiting a long time.
Their long term prospects are worth a look at, imho, with other drugs at stage 3 trials.:eek:
 
ACL announced that its drug trial didn't reach primary end point... share price collapsed by 90%.

The biotech sector is high risk for sure but I almost can't remember a good outcome for anyone bar SRX in the last few years.

ACR looked decent for a while until they ran into problems with the FDA.

TIS has been plagued with delay after delay.

QRX got annihilated in April after many false starts.

PBT god canned in March.

GID had a product recall last month.

PXS and PRR are both long term heart breakers.

AHZ, CUV and BNO's stories are still playing out.

I wonder what the statistics of this sector are in terms of win% and win/loss.
 
Yes, a great sector to lose a fortune in, similar to the junior oilers, but with success the rewards can be great. Probably best to treat them both similarly, enter early and exit or be at least free carried before results come out. That was my aim with this one, unfortunately got greedy and let 100% profit turn into a loss.
 
I'm surprised that nobody felt inclined to comment on the cap return and subsequent trading.
Okay, I didn't feel inclined to stir the pot either when I read about the 9.3c cash-back. But I took a punt and held on, even when trades rose above the 9.3c mark.

ACL preCB.png

First speculation was vindicated: After the cap return, price didn't go negative, so I didn't lose any.
Monday's announcement of a new Director, combined with the new "substantial holder", triggered the next alarm, and I put in a top-up-bid at 0.8c. Happy to see it's been filled BEFORE the breakout.

ACL postCB 09-03-16.png
 
The March "revival" looked promising, as if some new business were on the horizon.
That didn't come to fruition, and ACL will be suspended after end of trading today by ASX for lack of sufficient operation.
In other words: It's dead, which the chart showed a couple of months ago.
 
ACL is popping again, very little news on this stock so it might be one to watch. ACL into cancer therapies. Fair Value Estimate by Morning Star is 0.013. So its under-valued! Yes give me some more please!
 
Lots of on-market buying action has occurred on ACL at 0.01 cents over the past few trading days, wonder what is driving this? Is a new cancer therapy in the pipeline?
 
pettlepop said:
Lots of on-market buying action has occurred on ACL at 0.01 cents over the past few trading days, wonder what is driving this? Is a new cancer therapy in the pipeline?
Click to expand...

1. Total volume over last 3 days is a tad over 2m..
2. The price is 1c or $0.01, not 0.01 cent.
3. With 2m shares traded @ 1c, that's about $20k in value. So perhaps not exactly "lots of buying".
 
pettlepop said:
ACL going for a nice arvo rally. Take a look!
Click to expand...

pettlepop said:
ACL is popping again, very little news on this stock so it might be one to watch. ACL into cancer therapies. Fair Value Estimate by Morning Star is 0.013. So its under-valued! Yes give me some more please!
Click to expand...

pettlepop said:
Lots of on-market buying action has occurred on ACL at 0.01 cents over the past few trading days, wonder what is driving this? Is a new cancer therapy in the pipeline?
Click to expand...

Oh my how can this happen
The RSI is so over sold!
 
ACL seeing some movement in the new year. Price has doubled from around 1c to 2c on no news.

screenshot-shareinvesting.anz.com-2018-01-04-09-59-24.png


The ASX issued a speeding ticket yesterday but the company replied with the standard "we know nothing" response. Be interesting to see what this is all about. Time will tell.
 
On October 15th, 2019, Alchemia Limited (ACL) changed its name and ASX code to Australian Primary Hemp Limited (APH).
 
Top